NZ595125A - Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases - Google Patents

Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Info

Publication number
NZ595125A
NZ595125A NZ595125A NZ59512503A NZ595125A NZ 595125 A NZ595125 A NZ 595125A NZ 595125 A NZ595125 A NZ 595125A NZ 59512503 A NZ59512503 A NZ 59512503A NZ 595125 A NZ595125 A NZ 595125A
Authority
NZ
New Zealand
Prior art keywords
cancers
diseases
compositions
management
treatment
Prior art date
Application number
NZ595125A
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority claimed from NZ584663A external-priority patent/NZ584663A/en
Publication of NZ595125A publication Critical patent/NZ595125A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

595125 Disclosed is the use of the compound 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in the manufacture of a medicament for treating newly diagnosed multiple myeloma (NDMM).
NZ595125A 2002-05-17 2003-05-16 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases NZ595125A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38084202P 2002-05-17 2002-05-17
US42460002P 2002-11-06 2002-11-06
NZ584663A NZ584663A (en) 2002-05-17 2003-05-16 Use of immunomodulatory amino-dione derivatives for treating leukemia

Publications (1)

Publication Number Publication Date
NZ595125A true NZ595125A (en) 2013-10-25

Family

ID=49449200

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595125A NZ595125A (en) 2002-05-17 2003-05-16 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Country Status (4)

Country Link
CA (2) CA2855306A1 (en)
DK (1) DK2105135T3 (en)
NZ (1) NZ595125A (en)
SI (1) SI2105135T1 (en)

Also Published As

Publication number Publication date
SI2105135T1 (en) 2015-01-30
CA2855306A1 (en) 2003-11-27
DK2105135T3 (en) 2014-11-03
CA2855359A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
GB2392154B (en) Protein Kinase Inhibitors
MX346260B (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)- piperidine-2,6-dione.
LU92155I2 (en) Crizotinib, optionally in the form of a pharmaceutically acceptable salt, hydrate or solvate
IL178747A (en) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, for use in treating non-hodgkin's lymphoma, optionally in combination with additional therapeutic agent(s)
GEP20084391B (en) Pyrazoles and methods of making and using the same
ATE440603T1 (en) 8-HYDROXYQUINOLINE DERIVATIVES
DE60319967D1 (en) METHOD FOR THE USE OF COMPOUNDS AND COMPOUNDS WITH IMMUNOMODULATIVE COMPOUNDS FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
HK1072006A1 (en) 1-Amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 (nk-1)antagonsists for the treatment of emesis, depression, anxiety and cough
GB0111523D0 (en) Chemical compounds
MX2009014208A (en) Heterocyclic compounds and use thereof as erk inhibitors.
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
ECSP055809A (en) 4-OXO-1- (3-REPLACED PHENYL) INHIBITORS -1,4-DIHYDRO-1,8-NAFTIRIDINA-3-CARBOXAMIDE OF PHOSPHODIESTERASE-4
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MY148125A (en) Compounds
MXPA05007115A (en) Novel cb 1 receptor inverse agonists.
MXPA04006555A (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists.
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
IS7315A (en) Replaced diketopiperazine as an oxytocin antagonist
DE602005011267D1 (en) BENZOFURAN AND BENZOTHIOPHONE DERIVATIVES SUITABLE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
TW200732304A (en) Piperidine derivatives
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MXPA04005809A (en) Protein kinase inhibitors.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 16 MAY 2016 BY HENRY HUGHES

Effective date: 20140312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 16 MAY 2023 BY IN-LEGAL LIMITED

Effective date: 20140823

EXPY Patent expired